Logo image of ALSPT.PA

SPARTOO (ALSPT.PA) Stock Fundamental Analysis

EPA:ALSPT - Euronext Paris - Matif - FR00140043Y1 - Common Stock - Currency: EUR

0.38  +0.01 (+2.15%)

Fundamental Rating

3

Taking everything into account, ALSPT scores 3 out of 10 in our fundamental rating. ALSPT was compared to 52 industry peers in the Specialty Retail industry. While ALSPT seems to be doing ok healthwise, there are quite some concerns on its profitability. ALSPT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ALSPT has reported negative net income.
ALSPT had a positive operating cash flow in the past year.
In multiple years ALSPT reported negative net income over the last 5 years.
In multiple years ALSPT reported negative operating cash flow during the last 5 years.
ALSPT.PA Yearly Net Income VS EBIT VS OCF VS FCFALSPT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 5M -5M -10M -15M -20M

1.2 Ratios

ALSPT's Return On Assets of -2.62% is on the low side compared to the rest of the industry. ALSPT is outperformed by 65.38% of its industry peers.
The Return On Equity of ALSPT (-7.89%) is worse than 65.38% of its industry peers.
With a decent Return On Invested Capital value of 7.75%, ALSPT is doing good in the industry, outperforming 71.15% of the companies in the same industry.
Industry RankSector Rank
ROA -2.62%
ROE -7.89%
ROIC 7.75%
ROA(3y)-3.05%
ROA(5y)-1%
ROE(3y)-9.05%
ROE(5y)-1.75%
ROIC(3y)N/A
ROIC(5y)N/A
ALSPT.PA Yearly ROA, ROE, ROICALSPT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

ALSPT has a Operating Margin of 3.72%. This is comparable to the rest of the industry: ALSPT outperforms 59.62% of its industry peers.
ALSPT's Operating Margin has improved in the last couple of years.
ALSPT has a better Gross Margin (50.88%) than 75.00% of its industry peers.
ALSPT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.72%
PM (TTM) N/A
GM 50.88%
OM growth 3Y26.27%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.43%
GM growth 5YN/A
ALSPT.PA Yearly Profit, Operating, Gross MarginsALSPT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ALSPT is creating some value.
Compared to 1 year ago, ALSPT has more shares outstanding
Compared to 1 year ago, ALSPT has an improved debt to assets ratio.
ALSPT.PA Yearly Shares OutstandingALSPT.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
ALSPT.PA Yearly Total Debt VS Total AssetsALSPT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ALSPT has an Altman-Z score of 1.69. This is a bad value and indicates that ALSPT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALSPT (1.69) is comparable to the rest of the industry.
ALSPT has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ALSPT would need 3.41 years to pay back of all of its debts.
The Debt to FCF ratio of ALSPT (3.41) is better than 76.92% of its industry peers.
ALSPT has a Debt/Equity ratio of 0.50. This is a neutral value indicating ALSPT is somewhat dependend on debt financing.
ALSPT has a Debt to Equity ratio of 0.50. This is comparable to the rest of the industry: ALSPT outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 3.41
Altman-Z 1.69
ROIC/WACC1.33
WACC5.82%
ALSPT.PA Yearly LT Debt VS Equity VS FCFALSPT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 1.83 indicates that ALSPT should not have too much problems paying its short term obligations.
ALSPT has a Current ratio of 1.83. This is amongst the best in the industry. ALSPT outperforms 82.69% of its industry peers.
A Quick Ratio of 0.70 indicates that ALSPT may have some problems paying its short term obligations.
The Quick ratio of ALSPT (0.70) is better than 61.54% of its industry peers.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 0.7
ALSPT.PA Yearly Current Assets VS Current LiabilitesALSPT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

ALSPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.17%.
The Revenue has decreased by -8.71% in the past year.
The Revenue has been decreasing by -4.60% on average over the past years.
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1334.69%
Revenue 1Y (TTM)-8.71%
Revenue growth 3Y-4.6%
Revenue growth 5YN/A
Sales Q2Q%-6.86%

3.2 Future

The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
The Revenue is expected to decrease by -0.51% on average over the next years.
EPS Next Y-150%
EPS Next 2Y73.21%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-4.74%
Revenue Next 2Y-1.1%
Revenue Next 3Y-0.51%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALSPT.PA Yearly Revenue VS EstimatesALSPT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
ALSPT.PA Yearly EPS VS EstimatesALSPT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.1 -0.1 -0.2 -0.3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ALSPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSPT.PA Price Earnings VS Forward Price EarningsALSPT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALSPT indicates a rather cheap valuation: ALSPT is cheaper than 100.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALSPT indicates a rather cheap valuation: ALSPT is cheaper than 98.08% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 1.14
EV/EBITDA 0.99
ALSPT.PA Per share dataALSPT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.21%
EPS Next 3Y0%

More info and screens

0

5. Dividend

5.1 Amount

ALSPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPARTOO

EPA:ALSPT (8/8/2025, 7:00:00 PM)

0.38

+0.01 (+2.15%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners35.83%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.95M
Analysts82
Price Target0.82 (115.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF 1.14
P/OCF 1.06
P/B 0.23
P/tB 0.28
EV/EBITDA 0.99
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)0.33
FCFY87.82%
OCF(TTM)0.36
OCFY94.54%
SpS7.14
BVpS1.62
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.62%
ROE -7.89%
ROCE 10.54%
ROIC 7.75%
ROICexc 11.61%
ROICexgc 13.8%
OM 3.72%
PM (TTM) N/A
GM 50.88%
FCFM 4.68%
ROA(3y)-3.05%
ROA(5y)-1%
ROE(3y)-9.05%
ROE(5y)-1.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y13.91%
ROICexcg growth 5YN/A
ROICexc growth 3Y13.21%
ROICexc growth 5YN/A
OM growth 3Y26.27%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.43%
GM growth 5YN/A
F-Score3
Asset Turnover1.47
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 3.41
Debt/EBITDA 1.18
Cap/Depr 6.11%
Cap/Sales 0.36%
Interest Coverage 250
Cash Conversion 52.52%
Profit Quality N/A
Current Ratio 1.83
Quick Ratio 0.7
Altman-Z 1.69
F-Score3
WACC5.82%
ROIC/WACC1.33
Cap/Depr(3y)16.79%
Cap/Depr(5y)31.52%
Cap/Sales(3y)0.76%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1334.69%
EPS Next Y-150%
EPS Next 2Y73.21%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.71%
Revenue growth 3Y-4.6%
Revenue growth 5YN/A
Sales Q2Q%-6.86%
Revenue Next Year-4.74%
Revenue Next 2Y-1.1%
Revenue Next 3Y-0.51%
Revenue Next 5YN/A
EBIT growth 1Y59.21%
EBIT growth 3Y20.46%
EBIT growth 5YN/A
EBIT Next Year315.84%
EBIT Next 3Y72.78%
EBIT Next 5YN/A
FCF growth 1Y84.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.49%
OCF growth 3YN/A
OCF growth 5YN/A